Vas Narasimhan: US FDA has approved our CDK4/6 inhibitor to reduce risk of recurrence in people with HR+/HER2 early breast cancer

Vas Narasimhan posted on LinkedIn:

“I’m proud to share the news that the US FDA has approved our CDK4/6 inhibitor to reduce risk of recurrence in people with HR+/HER2- stage II and III early breast cancer. Up until now, only a limited amount of patients were eligible to leverage targeted therapies to help reduce the risk of their cancer coming back, and now many more may have a new treatment option.

Over the past 35 years, Novartis has continued to build on its long legacy in breast cancer—and we couldn’t have done so without the strength of partnerships and collaboration both within and outside of our company.

Thank you to everyone who helped us along on this journey and to all those working with us to reimagine medicine.”

Source: Vas Narasimhan/LinkedIn

Vas Narasimhan is the Chief Executive Officer of Novartis. Previously, he served as Global Head of Drug Development and Chief Medical Officer. As CEO, he has focused on driving innovation and empowering employees to advance new medical solutions.